Colorectal cancer (CRC) is the third most common cancer in men and women in the United States. Raman Molecular Imaging (RMI) is an effective technique to evaluate human tissue, cells and bodily fluids, including blood serum for disease diagnosis. ChemImage Corporation, in collaboration with clinicians, has been engaged in development of an in vitro diagnostic Raman assay focused on CRC detection. The Raman Assay for Colorectal Cancer (RACC) exploits the high specificity of Raman imaging to distinguish diseased from normal dried blood serum droplets without additional reagents. Pilot Study results from testing of hundreds of biobank patient samples have demonstrated that RACC detects CRC with high sensitivity and specificity. However, expanded clinical trials, which are ongoing, are revealing a host of important preanalytical considerations associated with sample collection, sample storage and stability, sample shipping, sample preparation and sample interferents, which impact detection performance. Results from recent clinical studies will be presented.
Patrick J. Treado, Shona D. Stewart, Aaron Smith, Heather Kirschner, Christopher Post, and Bergein F. Overholt M.D., "Preanalytical considerations in detection of colorectal cancer in blood serum using Raman molecular imaging
(Conference Presentation)," Proc. SPIE 9704, Biomedical Vibrational Spectroscopy 2016: Advances in Research and Industry, 970409 (Presented at SPIE BiOS: February 13, 2016; Published: 3 May 2016); https://doi.org/10.1117/12.2212776.4848737099001.
Conference Presentations are recordings of oral presentations given at SPIE conferences and published as part of the proceedings. They include the speaker's narration with video of the slides and animations. Most include full-text papers. Interactive, searchable transcripts and closed captioning are now available for most presentations.
Search our growing collection of more than 26,000 conference presentations, including many plenaries and keynotes.